• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Advocacy Group Worries European COVID-19 Trials Won’t Publish Results

Advocacy Group Worries European COVID-19 Trials Won’t Publish Results

June 29, 2020

A majority of European clinical trials of COVID-19 drugs are being run by universities and companies who either lack experience or have a poor track record in uploading their results to the EU’s trial database, which could lead to wasted research, according to a new report.

The report, issued by the nonprofit research advocacy group TranspariMED, analyzed 118 clinical trials of potential COVID-19 treatments across Europe and found that a majority of them (79) are being conducted by researchers who have never uploaded clinical trial results onto EudraCT, the EU’s clinical trials database.

Of those, 39 are being run by sponsors who have violated the EU’s trial transparency regulations in the past, while 40 trials are being run by sponsors that have never completed drug trials before and have never engaged in the uploading process, TranspariMED determined.

Only eight of the remaining 39 trials are being conducted by sponsors that have been fully compliant with the EU’s trial transparency rules.

“The large number of COVID-19 trials run by noncompliant and inexperienced trial sponsors poses a threat to the accuracy and utility of data on EudraCT, creating a high risk of research waste,” the group said. “This undermines the global search for safe and effective COVID-19 drugs.”

The report called for policy action to help address the issue. For example, it called on EU regulators to keep a close eye on COVID-19 trials in their countries and reach out to companies and universities to inform them of their data uploading obligations. They can go further by actively monitoring compliance and providing sponsors with guidance and training materials, the group said.

Additionally, regulators should encourage sponsors to upload their results as soon as possible after their trials conclude, rather than within 12 months as currently required by EU regulations since 2014, and sanction those that neglect to make their trial results public.

Read the full report here: https://bit.ly/3eFJPTy.

COVID-19
  • Related Directories

    Olumiant (baricitinib)

    Veklury (remdesivir)

    Comirnaty (COVID-19 Vaccine, mRNA)

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing